News

> September 2009
Poxel earns €430,000 grant from public organizations for a cooperative project named NATHEB

Project co-financed by the European Union

LYON BIOPOLE

PRESS RELEASE

Three new R&D projects accredited by Lyonbiopole obtain public funding from the 8^th Call for Projects of the Single Inter-Ministry Fund

Lyon/Grenoble, September 20, 2009 – Thanks to the accreditation of Lyonbiopôle, worldwide competitiveness cluster, the EXPAND ID, NATHEB and PATVAX R&D projects will receive € 6 million public funding.

Those three R&D projects, accredited by Lyonbiopôle and submitted in 2009 in response of the 8^th call for projects of FUI, benefit from public funding: the State (FUI) and also the European Regional Development Fund (EDFR), and regional authorities: the Rhône-Alpes Region, Greater Lyon, Grenoble Alpes Metropole and the city of Grenoble.

NATHEB: new therapeutic approaches in the treatment of chronic hepatitis B

Partners:

o EDELRIS (Lyon, France) (project leader)

o POXEL (Lyon, France),

o TRANSGENE Département Maladies Infectieuses (Lyon, France),

o Inserm U851, Vincent Lotteau (Lyon, France),

The aim of the project is to develop new therapeutic solutions against hepatitis B, which despite the efficacy of current vaccines, strikes over 350 million people in the world, and particularly in emerging countries. These new treatments will allow a better control over replication of the viral genome and viral antigen expression as well as a better stimulation of the host immune response.